Merck and Co Inc/ US58933Y1055 /
2024-05-31 10:10:00 PM | Chg. +1.01 | Volume | Bid2:00:00 AM | Ask2:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
125.54USD | +0.81% | 18.15 mill. Turnover: 1.39 bill. |
125.56Bid Size: 400 | 131.03Ask Size: 100 | 317.97 bill.USD | 2.36% | 896.71 |
GlobeNewswire
05-28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
05-23
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
05-16
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-14
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
04-24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-09
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer...
GlobeNewswire
03-18
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...